Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries
Abstract Background In a number of malaria endemic regions, tourists and travellers face a declining risk of travel associated malaria, in part due to successful malaria control. Many millions of visitors to these regions are recommended, via national and international policy, to use chemoprophylaxi...
Published in: | Malaria Journal |
---|---|
Main Authors: | , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMC
2011
|
Subjects: | |
Online Access: | https://doi.org/10.1186/1475-2875-10-130 https://doaj.org/article/376f9245d99042e78f76540d126aedbb |
id |
ftdoajarticles:oai:doaj.org/article:376f9245d99042e78f76540d126aedbb |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:376f9245d99042e78f76540d126aedbb 2023-05-15T15:16:12+02:00 Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries Coutinho Francisco AB Behrens Ben C Massad Eduardo Behrens Ronald H 2011-05-01T00:00:00Z https://doi.org/10.1186/1475-2875-10-130 https://doaj.org/article/376f9245d99042e78f76540d126aedbb EN eng BMC http://www.malariajournal.com/content/10/1/130 https://doaj.org/toc/1475-2875 doi:10.1186/1475-2875-10-130 1475-2875 https://doaj.org/article/376f9245d99042e78f76540d126aedbb Malaria Journal, Vol 10, Iss 1, p 130 (2011) Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2011 ftdoajarticles https://doi.org/10.1186/1475-2875-10-130 2022-12-31T09:13:48Z Abstract Background In a number of malaria endemic regions, tourists and travellers face a declining risk of travel associated malaria, in part due to successful malaria control. Many millions of visitors to these regions are recommended, via national and international policy, to use chemoprophylaxis which has a well recognized morbidity profile. To evaluate whether current malaria chemo-prophylactic policy for travellers is cost effective when adjusted for endemic transmission risk and duration of exposure. a framework, based on partial cost-benefit analysis was used Methods Using a three component model combining a probability component, a cost component and a malaria risk component, the study estimated health costs avoided through use of chemoprophylaxis and costs of disease prevention (including adverse events and pre-travel advice for visits to five popular high and low malaria endemic regions) and malaria transmission risk using imported malaria cases and numbers of travellers to malarious countries. By calculating the minimal threshold malaria risk below which the economic costs of chemoprophylaxis are greater than the avoided health costs we were able to identify the point at which chemoprophylaxis would be economically rational. Results The threshold incidence at which malaria chemoprophylaxis policy becomes cost effective for UK travellers is an accumulated risk of 1.13% assuming a given set of cost parameters. The period a travellers need to remain exposed to achieve this accumulated risk varied from 30 to more than 365 days, depending on the regions intensity of malaria transmission. Conclusions The cost-benefit analysis identified that chemoprophylaxis use was not a cost-effective policy for travellers to Thailand or the Amazon region of Brazil, but was cost-effective for travel to West Africa and for those staying longer than 45 days in India and Indonesia. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Malaria Journal 10 1 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
spellingShingle |
Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 Coutinho Francisco AB Behrens Ben C Massad Eduardo Behrens Ronald H Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries |
topic_facet |
Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
description |
Abstract Background In a number of malaria endemic regions, tourists and travellers face a declining risk of travel associated malaria, in part due to successful malaria control. Many millions of visitors to these regions are recommended, via national and international policy, to use chemoprophylaxis which has a well recognized morbidity profile. To evaluate whether current malaria chemo-prophylactic policy for travellers is cost effective when adjusted for endemic transmission risk and duration of exposure. a framework, based on partial cost-benefit analysis was used Methods Using a three component model combining a probability component, a cost component and a malaria risk component, the study estimated health costs avoided through use of chemoprophylaxis and costs of disease prevention (including adverse events and pre-travel advice for visits to five popular high and low malaria endemic regions) and malaria transmission risk using imported malaria cases and numbers of travellers to malarious countries. By calculating the minimal threshold malaria risk below which the economic costs of chemoprophylaxis are greater than the avoided health costs we were able to identify the point at which chemoprophylaxis would be economically rational. Results The threshold incidence at which malaria chemoprophylaxis policy becomes cost effective for UK travellers is an accumulated risk of 1.13% assuming a given set of cost parameters. The period a travellers need to remain exposed to achieve this accumulated risk varied from 30 to more than 365 days, depending on the regions intensity of malaria transmission. Conclusions The cost-benefit analysis identified that chemoprophylaxis use was not a cost-effective policy for travellers to Thailand or the Amazon region of Brazil, but was cost-effective for travel to West Africa and for those staying longer than 45 days in India and Indonesia. |
format |
Article in Journal/Newspaper |
author |
Coutinho Francisco AB Behrens Ben C Massad Eduardo Behrens Ronald H |
author_facet |
Coutinho Francisco AB Behrens Ben C Massad Eduardo Behrens Ronald H |
author_sort |
Coutinho Francisco AB |
title |
Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries |
title_short |
Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries |
title_full |
Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries |
title_fullStr |
Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries |
title_full_unstemmed |
Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries |
title_sort |
cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries |
publisher |
BMC |
publishDate |
2011 |
url |
https://doi.org/10.1186/1475-2875-10-130 https://doaj.org/article/376f9245d99042e78f76540d126aedbb |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Malaria Journal, Vol 10, Iss 1, p 130 (2011) |
op_relation |
http://www.malariajournal.com/content/10/1/130 https://doaj.org/toc/1475-2875 doi:10.1186/1475-2875-10-130 1475-2875 https://doaj.org/article/376f9245d99042e78f76540d126aedbb |
op_doi |
https://doi.org/10.1186/1475-2875-10-130 |
container_title |
Malaria Journal |
container_volume |
10 |
container_issue |
1 |
_version_ |
1766346486745923584 |